An observational study in Acromegaly, sponsored by Ipsen. Completed at 39 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-05.
Sponsored by Ipsen · Observational
The purpose of this study is to evaluate the effectiveness in IGF-1 control of lanreotide Autogel (ATG) 120 mg at extended dosing intervals (EDIs) (>4 weeks) in subjects with acromegaly in daily clinical practice.
203 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
This study's enrollment of 115 is above the median of 100 across 81 observational studies indexed under Acromegaly.
Browse Acromegaly studies →Ipsen is the lead sponsor of 288 studies on the registry; 16 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 21 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Hospital patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Percentage of subjects with a normal Insulin-like Growth Factor 1 (IGF-1) level in the assay before the study visit.
Time frame: Day 1
Percentage of subjects with Growth hormone (GH) levels ≤ 2.5 ng/mL or ≤ 1 ng/mL in the assay before the study visit.
Time frame: Day 1
Percentage of subjects treated with lanreotide autogel (ATG) 120 mg for ≥ 6 months with dosing intervals of five, six, seven or eight weeks.
Time frame: Day 1
Percentage of subjects whose dosing regimen has been changed in the six months before the study.
Time frame: Day 1
Preference for self-administered injections or administration in an outpatient clinic by a medical professional.
Time frame: Day 1
Acromegaly Quality of Life Questionnaire (AcroQoL) in subjects after ≥ 5 months of treatment with ATG 120 mg at extended dosing intervals.
Total score and score per domain
Time frame: Day 1
EuroQol-5D (EQ-5D) questionnaire in subjects after ≥ 5 months of treatment with ATG 120 mg at extended dosing intervals.
Total score and score per domain
Time frame: Day 1
Treatment Satisfaction Questionnaire for Medication-9 (TSMQ-9) in subjects treated with ATG 120 mg at extended dosing intervals after ≥ 5 months.
Total score and score per domain
Time frame: Day 1
Variations between theoretical and real treatment compliance for non-medical reasons.
Time frame: Day 1
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.